Advanced Oncotherapy PLC Company Profile (LON:AVO)

About Advanced Oncotherapy PLC (LON:AVO)

Advanced Oncotherapy PLC logoAdvanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device and management of healthcare related property. The Company's segments include Development of Proton Therapy-UK; Development of Proton Therapy-Switzerland; Development of Proton Therapy-USA, and Healthcare-related properties-UK. Its LIGHT system uses accelerators, which is a series of modular units. This feature offers hospitals and centers to customize treatment plans based on a range of energies. The Company's Research and development/ADAM S.A. (R&D/ADAM) facility is located on the campus of European Council for Nuclear Research (CERN), Geneva, Switzerland, and a manufacturing plant, clinical research and clinician training facility in Syracuse, the United States.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: N/A
  • Symbol: LON:AVO
  • CUSIP: N/A
  • Web:
  • Market Cap: £14.49 million
  • Outstanding Shares: 72,467,000
Average Prices:
  • 50 Day Moving Avg: GBX 17.71
  • 200 Day Moving Avg: GBX 22.27
  • 52 Week Range: GBX 9.75 - GBX 120
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: GBX 0.47 per share
  • Price / Book: 0.43
  • EBIDTA: ($12,740,000.00)
  • Return on Equity: -31.23%
  • Return on Assets: -26.68%
  • Average Volume: 265,356 shs.

Frequently Asked Questions for Advanced Oncotherapy PLC (LON:AVO)

What is Advanced Oncotherapy PLC's stock symbol?

Advanced Oncotherapy PLC trades on the London Stock Exchange (LON) under the ticker symbol "AVO."

Who are some of Advanced Oncotherapy PLC's key competitors?

Who are Advanced Oncotherapy PLC's key executives?

Advanced Oncotherapy PLC's management team includes the folowing people:

  • Michael J. Sinclair, Executive Chairman of the Board
  • Nicolas Serandour, Chief Executive Officer, Executive Director
  • Sanjeev Pandya, Executive Vice President - Global Business Development, Executive Director
  • Richard Amos, Director of Medical Physics
  • Michel Baelen, Head of Regulatory Affairs
  • Gerardo DAuria, Technical Director
  • Michael R. Graham, Global Head of QMS and Product Realisation
  • Donatella Ungaro, ADAM Managing Director Based at CERN
  • Michael Bradfield, Non-Executive Director
  • Steve Myers, Non-Executive Director

How do I buy Advanced Oncotherapy PLC stock?

Shares of Advanced Oncotherapy PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Advanced Oncotherapy PLC's stock price today?

One share of Advanced Oncotherapy PLC stock can currently be purchased for approximately GBX 20.

MarketBeat Community Rating for Advanced Oncotherapy PLC (LON AVO)
Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  75 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  225
MarketBeat's community ratings are surveys of what our community members think about Advanced Oncotherapy PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Advanced Oncotherapy PLC (LON:AVO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Advanced Oncotherapy PLC (LON:AVO)
DateFirmActionRatingPrice TargetDetails
2/27/2017Beaufort SecuritiesDowngradeHoldView Rating Details
(Data available from 9/22/2015 forward)


Earnings History for Advanced Oncotherapy PLC (LON:AVO)
No earnings announcements for this company have been tracked by


Earnings Estimates for Advanced Oncotherapy PLC (LON:AVO)
Current Year EPS Consensus Estimate: $-6.71 EPS


Dividend History for Advanced Oncotherapy PLC (LON:AVO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Advanced Oncotherapy PLC (LON:AVO)
Insider Trades by Quarter for Advanced Oncotherapy PLC (LON:AVO)
Insider Trades by Quarter for Advanced Oncotherapy PLC (LON:AVO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/31/2017Enrico Cipro VanniInsiderBuy100,000GBX 18£18,000
5/15/2017Steve Myers OBEInsiderBuy400,000GBX 26£104,000
5/9/2017Christopher NuttingInsiderBuy202,500GBX 25£50,625
4/25/2017Michael J SinclairInsiderBuy200,000GBX 30£60,000
4/24/2017Enrico Cipro VanniInsiderBuy100,000GBX 27£27,000
4/12/2017Enrico Cipro VanniInsiderBuy100,000GBX 28£28,000
4/4/2017Enrico Cipro VanniInsiderBuy25,000GBX 29£7,250
4/3/2017Michael J SinclairInsiderBuy100,000GBX 28£28,000
1/3/2017Enrico Cipro VanniInsiderBuy25,000GBX 87£21,750
12/29/2016Enrico Cipro VanniInsiderBuy25,000GBX 66£16,500
12/22/2016Enrico Cipro VanniInsiderBuy25,000GBX 60£15,000
12/20/2016Enrico Cipro VanniInsiderBuy25,000GBX 55£13,750
12/19/2016Enrico Cipro VanniInsiderBuy25,000GBX 50£12,500
7/11/2016Bradfield ,MichaelInsiderBuy30,000GBX 135£40,500
7/8/2016Bradfield ,MichaelInsiderBuy10,000GBX 120£12,000
7/7/2016Bradfield ,MichaelInsiderBuy10,000GBX 112£11,200
7/6/2016Bradfield ,MichaelInsiderBuy50,000GBX 102£51,000
12/18/2015Bradfield ,MichaelInsiderBuy750,000GBX 7£52,500
12/17/2015Bradfield ,MichaelInsiderBuy1,000,000GBX 6£60,000
12/16/2015Bradfield ,MichaelInsiderBuy750,000GBX 6£45,000
7/20/2015Vanni ,Enrico CiproInsiderBuy1,000,000GBX 8£80,000
7/1/2015Sinclair,Michael JInsiderSell7,000,000GBX 0.08£5,600
6/5/2015Michael BradfieldInsiderBuy1,500,000GBX 9.81£147,150
2/4/2015Michael BradfieldInsiderBuy500,000GBX 4.10£20,500
(Data available from 1/1/2013 forward)


Headline Trends for Advanced Oncotherapy PLC (LON:AVO)
Latest Headlines for Advanced Oncotherapy PLC (LON:AVO)
DateHeadline logoProton Therapy Systems Market Analysis By Product, By Type, By Region And Segment Forecasts, 2014 - 2025 - August 23 at 4:17 PM logoInsider Buying: Advanced Oncotherapy PLC (AVO) Insider Acquires 100,000 Shares of Stock - August 1 at 7:41 AM logoAdvanced Oncotherapy PLC (AVO) Insider Buys £104,000 in Stock - May 17 at 7:18 AM logoInsider Buying: Advanced Oncotherapy PLC (AVO) Insider Buys 202,500 Shares of Stock - May 15 at 7:10 AM logoAdvanced Oncotherapy PLC (AVO) Insider Michael J. Sinclair Buys 200,000 Shares - April 26 at 8:21 AM logoAdditional financing agreement - London South East (registration) (blog) - April 25 at 3:41 PM logoAdvanced Oncotherapy PLC (AVO) Insider Acquires £28,000 in Stock - April 18 at 7:21 AM logoAdvanced Oncotherapy Plc breached its 50 day moving average in a Bullish Manner : AVO-GB : July 13, 2016 - April 7 at 8:13 AM logoAdvanced Oncotherapy PLC (AVO) Insider Purchases £7,250 in Stock - April 5 at 12:37 PM logoInsider Buying: Advanced Oncotherapy PLC (AVO) Insider Purchases 100,000 Shares of Stock - April 4 at 11:37 AM logoAdvanced Oncotherapy PLC (AVO) Stock Rating Lowered by Beaufort Securities - March 26 at 6:49 AM logo[$$] Shareholders risk paying high costs for extreme funding arrangements - February 28 at 11:29 AM


Social activity is not available for this stock.


Advanced Oncotherapy PLC (AVO) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by Staff